Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Should l Buy ?
Source: PRnewswire
Endo's Presentations at APMA Annual Meeting: Endo, Inc. announced three presentations on plantar fibromatosis (PFI) and plantar fasciitis (PFA) during the American Podiatric Medical Association Annual Meeting, highlighting findings from clinical trials involving collagenase clostridium histolyticum (CCH) and patient experiences with PFI.
Commitment to Non-Surgical Treatments: The company is advancing a Phase 3 study for a potential nonsurgical treatment option for PFI, responding to patient dissatisfaction with current treatments and emphasizing the need for effective therapies that manage symptoms and halt nodule growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
